Early intervention with lenalidomide in patients with high-risk chronic lymphocytic leukemia.

CONCLUSION: Lenalidomide is efficacious with manageable toxicities as an early intervention strategy in patients with high-risk CLL, but did not enhance humoral response to PCV13 vaccine. This trial was registered with ClinicalTrials.gov Identifier: NCT01351896.
PMID: 32958702 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - September 20, 2020 Category: Cancer & Oncology Authors: Thangavadivel S, Zhao Q, Epperla N, Rike LA, Mo X, Badawi M, Bystry D, Phelps MA, Andritsos L, Rogers KA, Jones J, Woyach JA, Byrd JC, Awan FT Tags: Clin Cancer Res Source Type: research